查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386506

原发性免疫力缺乏治疗市场报告：2030 年趋势、预测与竞争分析

Primary Immunodeficiency Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

原发性免疫力缺乏治疗的趋势和预测

至2030年，全球原发性免疫力缺乏治疗市场预计将达到111亿美元，2024年至2030年的年复合成长率为6.3%。该市场的主要驱动力是人们对原发性免疫力缺乏疾病的认识不断提高、基因组研究的活性化以及基因检测、流式细胞仪和次世代定序诊断技术的不断进步。全球原发性免疫力缺乏治疗市场前景广阔，免疫球蛋白替代治疗、干细胞/骨髓移植、抗生素治疗、基因治疗市场都有机会。

原发性免疫力缺乏治疗市场洞察

Lucintel 预测，由于人们对该疾病的认识不断增强，而且高龄化使其更容易受到抗体缺乏的影响，抗体缺乏仍将是最大的部分。

在这个市场中，免疫球蛋白替代疗法预计仍将是最大的部分，因为它有助于改善免疫系统功能并降低原发性免疫力缺乏缺陷疾病患者的感染疾病风险。

由于原发性免疫力缺乏疾病的高盛行率以及原发性免疫力缺乏治疗的报销，北美将继续成为最大的市场。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2. 哪个产业将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10.这个市场有哪些竞争产品？此外，由于疾病类型或替代品而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球原发性免疫力缺乏治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球原发性免疫力缺乏治疗市场趋势（2018-2023）和预测（2024-2030）
  • 按类型分類的全球原发性免疫力缺乏治疗市场
    • 免疫球蛋白替代疗法
    • 干细胞/骨髓移植
    • 抗生素治疗
    • 基因治疗
    • 其他的
  • 按疾病类型分類的全球原发性免疫力缺乏治疗市场
    • 抗体缺乏
    • 细胞免疫力缺乏
    • 先天性免疫疾病
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球原发性免疫力缺乏治疗市场（按地区）
  • 北美原发性免疫力缺乏治疗市场
  • 欧洲原发性免疫力缺乏治疗市场
  • 亚太地区原发性免疫力缺乏治疗市场
  • 其他区域原发性免疫力缺乏治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 全球原发性免疫力缺乏治疗市场成长机会（按类型）
    • 按疾病类型分類的全球原发性免疫力缺乏治疗市场成长机会
    • 按地区分類的全球原发性免疫力缺乏治疗市场成长机会
  • 全球原发性免疫力缺乏治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球原发性免疫力缺乏治疗市场的产能
    • 全球原发性免疫力缺乏治疗市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Pfizer
  • CSL Behring
  • Grifols
  • Abbott
  • ADMA Biologics
  • AstraZeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb
简介目录

Primary Immunodeficiency Therapeutics Trends and Forecast

The future of the global primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets. The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.

A more than 150-page report is developed to help in your business decisions.

Primary Immunodeficiency Therapeutics by Segment

The study includes a forecast for the global primary immunodeficiency therapeutics by type, disease type, and region.

Primary Immunodeficiency Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Immunoglobulin Replacement Therapy
  • Stem Cell/Bone Marrow Transplantation
  • Antibiotic Therapy
  • Gene Therapy
  • Others

Primary Immunodeficiency Therapeutics Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Antibody Deficiency
  • Cellular Immunodeficiency
  • Innate Immune Disorders
  • Others

Primary Immunodeficiency Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Primary Immunodeficiency Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies primary immunodeficiency therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the primary immunodeficiency therapeutics companies profiled in this report include-

  • Pfizer
  • CSL Behring
  • Grifols
  • Abbott
  • Adma Biologics
  • Astrazeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb

Primary Immunodeficiency Therapeutics Market Insights

Lucintel forecasts that antibody deficiency will remain the largest segment due to increasing awareness of antibody deficiency and aging population is more susceptible to antibody deficiency.

Within this market, immunoglobulin replacement therapy is expected to remain the largest segment as it helps to improve the immune system function and also reduces the risk of infections in primary immunodeficiency disorders patients.

North America will remain the largest segment due to high prevalence of primary immunodeficiency disorders and availability of reimbursement for primary immunodeficiency disorders therapeutics.

Features of the Global Primary Immunodeficiency Therapeutics Market

Market Size Estimates: Primary immunodeficiency therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Primary immunodeficiency therapeutics market size by type, disease type, and region in terms of value ($B).

Regional Analysis: Primary immunodeficiency therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, disease types, and regions for the primary immunodeficiency therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the primary immunodeficiency therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the primary immunodeficiency therapeutics market size?

Answer: The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030.

Q.2 What is the growth forecast for primary immunodeficiency therapeutics market?

Answer: The global primary immunodeficiency therapeutics market is expected to grow with a CAGR of 6.3% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the primary immunodeficiency therapeutics market?

Answer: The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.

Q4. What are the major segments for primary immunodeficiency therapeutics market?

Answer: The future of the primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets.

Q5. Who are the key primary immunodeficiency therapeutics market companies?

Answer: Some of the key primary immunodeficiency therapeutics companies are as follows:

  • Pfizer
  • CSL Behring
  • Grifols
  • Abbott
  • Adma Biologics
  • Astrazeneca
  • Baxter
  • Bayer
  • Biocon
  • Bristol-Myers Squibb

Q6. Which primary immunodeficiency therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that antibody deficiency will remain the largest segment due to increasing awareness of antibody deficiency and aging population is more susceptible to antibody deficiency.

Q7. In primary immunodeficiency therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment due to high prevalence of primary immunodeficiency disorders and availability of reimbursement for primary immunodeficiency disorders therapeutics.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the primary immunodeficiency therapeutics market by type (immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, gene therapy, and others), disease type (antibody deficiency, cellular immunodeficiency, innate immune disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by disease type or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Primary Immunodeficiency Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Primary Immunodeficiency Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Primary Immunodeficiency Therapeutics Market by Type
    • 3.3.1: Immunoglobulin Replacement Therapy
    • 3.3.2: Stem Cell/Bone Marrow Transplantation
    • 3.3.3: Antibiotic Therapy
    • 3.3.4: Gene Therapy
    • 3.3.5: Others
  • 3.4: Global Primary Immunodeficiency Therapeutics Market by Disease Type
    • 3.4.1: Antibody Deficiency
    • 3.4.2: Cellular Immunodeficiency
    • 3.4.3: Innate Immune Disorders
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Primary Immunodeficiency Therapeutics Market by Region
  • 4.2: North American Primary Immunodeficiency Therapeutics Market
    • 4.2.2: North American Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others
  • 4.3: European Primary Immunodeficiency Therapeutics Market
    • 4.3.1: European Primary Immunodeficiency Therapeutics Market by Type: Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others
    • 4.3.2: European Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others
  • 4.4: APAC Primary Immunodeficiency Therapeutics Market
    • 4.4.1: APAC Primary Immunodeficiency Therapeutics Market by Type: Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others
    • 4.4.2: APAC Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others
  • 4.5: ROW Primary Immunodeficiency Therapeutics Market
    • 4.5.1: ROW Primary Immunodeficiency Therapeutics Market by Type: Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others
    • 4.5.2: ROW Primary Immunodeficiency Therapeutics Market by Disease Type: Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Primary Immunodeficiency Therapeutics Market by Type
    • 6.1.2: Growth Opportunities for the Global Primary Immunodeficiency Therapeutics Market by Disease Type
    • 6.1.3: Growth Opportunities for the Global Primary Immunodeficiency Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Primary Immunodeficiency Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Primary Immunodeficiency Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Primary Immunodeficiency Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: CSL Behring
  • 7.3: Grifols
  • 7.4: Abbott
  • 7.5: ADMA Biologics
  • 7.6: AstraZeneca
  • 7.7: Baxter
  • 7.8: Bayer
  • 7.9: Biocon
  • 7.10: Bristol-Myers Squibb